arrow
M

Masafumi Ikeda

National Cancer Center Hospital East
H指数:76
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single-Center Japanese Retrospective Cohort Study

血液学免疫相关不良事件的发生率、临床特征、管理及结局:一项日本单中心回顾性队列研究

2026-10-070
OAAI
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study

度伐利尤单抗联合吉西他滨为基础的化疗方案在晚期胆道癌中的应用:TOURMALINE IIIb期研究的主要结果

2026-07-060
OAAI
Clinical Implications of Polyploid Giant Cancer Cells in Solid Tumors: Biology, Diagnosis, and Therapeutic Considerations

实体瘤中多倍体巨癌细胞的治疗意义:生物学、诊断和治疗考量

Cancers
IF4.4
2026-06-010
OA
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study

全国性前瞻性研究中的真实世界证据:不可切除肝细胞癌系统性治疗的有效性/安全性分析——PRISM研究的前1000例患者

2026-05-010
PRE
daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

daNIS-2:一项评估抗TGF-β单克隆抗体NIS793或安慰剂联合nab-紫杉醇/吉西他滨作为转移性胰腺导管腺癌患者一线治疗的III期、随机、双盲研究

2026-01-010
OA
Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial

不可切除性肝细胞癌行选择性肝动脉化疗栓塞术后的肝功能变化:JIVROSG-2001 PRESIDENT-ALBI——一项多中心随机对照试验的二次分析

2025-12-010
OA
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)

多中心回顾性研究:系统性疗法在神经内分泌肿瘤3级患者中的疗效(JOSC-2001)

2025-09-010
PRE
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼作为不可切除肝细胞癌的一线治疗:CheckMate 9DW日本亚组分析

2025-09-016
OA
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Outcomes of FOLFIRINOX versus Gemcitabine plus nab-Paclitaxel in Patients with Early Recurrent Pancreatic Cancer after Adjuvant S-1 Treatment: A propensity Score-matched Analysis

FOLFIRINOX与吉西他滨联合nab-紫杉醇在S-1辅助治疗后早期复发性胰腺癌患者中的疗效比较:一项倾向性评分匹配分析

2025-08-300
PRE
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

LEAP-002研究:lenvatinib联合pembrolizumab对比lenvatinib单药作为晚期肝细胞癌一线治疗的健康相关生活质量分析

2025-06-010
OA
Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer (vol 23, 23, 2025)

稳健的循环microRNA特征,用于胰腺癌和胆道癌的诊断与早期检测(卷23,期23,2025)

2025-04-160
OA
Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer
2025-01-210
OAAI